MARKET DEFINITION

The Middle East respiratory syndrome (MERS) is a viral respiratory infection caused by the novel coronavirus, also referred to as MERS‐CoV and was originally discovered in Saudi Arabia in 2012. A broad family of viruses known as coronaviruses is responsible for the common cold, fever, and Severe Acute Respiratory Syndrome (SARS). MERS can cause coughing, fever, respiratory issues, and pneumonia, but these symptoms are not always present. Additionally, reports of gastrointestinal issues, such as diarrhoea, have been made. Some MERS-CoV patients reported being asymptomatic, meaning they had no signs of illness yet are nonetheless infected and spread the disease to others.  

MARKET DYNAMICS

Oral medications for MERS are anticipated to accelerate market expansion. Since the majority of the goods are accessible in capsule and tablet form and are a highly practical method of administration, these pharmaceuticals are anticipated to accelerate the worldwide market. Over the course of the projection period, the worldwide Middle East respiratory syndrome (MERS) market may see certain growth restraints due to a shortage of competent professionals who are unable to treat patients with these drugs. On the other hand, growing public awareness of pharmaceuticals and research being done by public and private organizations to discover the body's toxic components for a better understanding of these substances and their countermeasures are anticipated to propel market expansion.

REPORT SCOPE

The report titled “Global Respiratory Syndrome (MERS) Market – Size, Share, Growth, Opportunities, and Competitive Analysis, 2022 – 2028” offers strategic visions into the global Respiratory Syndrome (MERS) market along with the market size (Value in “US$ Mn”) for the historical period 2017 to 2021 and estimates for the forecast period 2022 to 2028. The RI report is an in-depth study of the global Respiratory Syndrome (MERS) market with a strong focus on key market trends, vital player strategies, and market forecasts. The study also covers key market dynamics, including drivers, restraints, opportunities, challenges, and existing and upcoming pathways that help CXOs make critical business decisions effectively. The global Respiratory Syndrome (MERS) Market is predicted to grow at a significant CAGR over the forecast period from 2022 to 2028.

GEOGRAPHICAL OVERVIEW

The research report includes a detailed overview of the industry comprising quantitative and qualitative information. It gives a broad overview of the worldwide market forecasts for major segments. It also includes market size and forecast projections for five key regions: North America, Europe, Asia-Pacific (APAC), South America, and the Middle East & Africa (MEA), for the years 2017 to 2028. The market is further divided by categories and countries within each province. The research scrutinizes and forecasts over 20 nations worldwide, as well as the present trend and possibilities in these regions.

 

MARKET SEGMENTATION

The Global Respiratory Syndrome (MERS) Market is segmented based on medicine, route of administration, end-users and region. Based on medicine, the market has been segmented into REGN3048, REGN3051, GLS-5300 and Others, whereas based on the route of administration, the market comprises Oral, Parenteral and Others. Based on end-users, the market has been segmented into Hospitals, Homecare, Specialty Clinics and Others.

COMPETITION LANDSCAPE

The RI research report discusses noteworthy developments in the industry as well as organic and inorganic growth strategies being adopted by the Respiratory Syndrome (MERS) market players. The report covers industry activities, including new product launches, mergers & acquisitions, business partnerships, and various expansion initiatives being undertaken by the active players in the market. These developments pave the path for various market participants to strengthen their positioning as well as expand their consumer base. The positive market outlook for the global Respiratory Syndrome (MERS) market is anticipated to present lucrative growth opportunities to the market players. The report also offers detailed profiles of major players in the global Respiratory Syndrome (MERS) market, emphasizing the strategic initiatives, financial information, SWOT analysis, and key development in the Respiratory Syndrome (MERS) industry in the past three years.

Key players in the Global Respiratory Syndrome (MERS) Market have adopted various organic as well as inorganic growth strategies to strengthen their market positioning. Prominent players in the market include:

·         GeneOne Life Science

·         INOVIO Pharmaceuticals

·         Regeneron Pharmaceuticals Inc

·         Astellas Pharma Inc.

·         Merck KGaA

·         Sanofi

·         Biocare Medical, LLC

·         Teva Pharmaceutical Industries Ltd

COVID-19 IMPACT ANALYSIS ON GLOBAL RESPIRATORY SYNDROME (MERS) MARKET

The COVID-19 pandemic is still a very personal, individual experience that is also a once-in-a-lifetime worldwide phenomenon with far-reaching consequences. The epidemic has wreaked havoc on people's lives in all nations and communities and also had a negative impact on global economic development in 2020, unlike anything seen in almost a century. The pandemic severely impacted key economies such as India, Brazil, the U.S., France, Russia, the UK, Italy, Turkey, and Argentina. According to estimates, the virus slowed global economic growth by -3.4 percent to -7.6 percent in 2020, with a rebound of 4.2 percent to 5.6 percent expected in 2021. In 2020, global commerce was expected to decline by 5.3 percent, but it is expected to rise by 8.0 percent in 2021.

In contrast to the global economic downturn in the first half of 2020, the economy began to showcase symptoms of a two-track recovery post the second quarter of 2020, with a fledgling rebound in developed nations, however, slower growth in emerging economies. The outbreak of the Covid-19 pandemic has not only resulted in halted production activity but has also disrupted the global supply chain. The research goes on to evaluate the current and future implications of the COVID-19 pandemic both on the target as well as broader market, thereby, providing accurate and trustworthy forecasts.

 

Report Attribute/Metric	Details
Market Size	In USD Million
CAGR	In % (2022-2028)
Base Year	2021
Forecast Period	2022 – 2028
Historical Data	2017 to 2021
Forecast Unit	Value (US$ Mn)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors and Trends
Geographies Covered	North America, Europe, Asia-Pacific, South America, and Middle East & Africa
Key Players Analyzed	GeneOne Life Science, INOVIO Pharmaceuticals, Regeneron Pharmaceuticals Inc, Astellas Pharma Inc, Merck KGa, Sanofi, Biocare Medical, LLC, Teva Pharmaceutical Industries Ltd
Customization & Pricing	Available on Request (10% Customization is Free)

 

RESEARCH PROGRAM DESIGN

KEY QUESTIONS ANSWERED

1.    What is the current size of the global Respiratory Syndrome (MERS) market?

2.    What will be the growth rate of the market over the forecast period?

3.    Who are the key manufacturers/vendors in the Respiratory Syndrome (MERS) market space?

4.    What are the major market opportunities and market risks faced by the market?

5.    What is the impact of COVID-19 on the market?

6.    What are the revenue, sales, and price analysis of the top manufacturers in this market?

7.    What are the key outcomes of Porter's five forces model?

8.    Who are the distributors, traders, and vendors in the industry?

REASONS FOR BUYING THIS REPORT:

·         The report offers comprehensive data on the Respiratory Syndrome (MERS) market elaborating on the current state and future growth prospects both globally and regionally

·         It offers a six-year market forecast trend evaluating the impact of drivers and restraints and supporting factors for growth

·         The report offers deep-dive insights into each market segment and critical factors responsible for its growth

·         The report presents precise picture of the dynamic competitive landscape which helps our client advance their market position

·         The comprehensive analysis of the market along with the inclusion of analyst recommendations ensures that our clients make informed business decisions

·         Cross-segment country-level analysis included in the report which provides granular analysis of more than 20+ countries covered in the report scope

·         The study includes detailed profiles of major manufacturers to help our readers gain holistic overview of the market competitors and consequently align their business strategies

 

Chapter 1.  Executive Summary

1.1.   Market Outlook

1.2.   Market Segment Outlook

1.3.   Geography Outlook

1.4.   Absolute $ Opportunity

Chapter 2.  Research Methodology

2.1.   Research Approach

2.2.   Scope, Definition, and Assumptions

2.3.   Data Sources

2.3.1. Secondary Sources

2.3.1.1.         Preliminary Data Mining

2.3.2. Primary Sources

2.3.2.1.         Statistical Model

2.3.2.2.         Data Triangulation

2.3.2.3.         Research Objective

Chapter 3.  Market Outlook

3.1.   Introduction

3.2.   Key Trends

3.2.1. Medicine Trends

3.2.2. Route of Administration Trends

3.2.3. End-Users Trends

3.3.   Market Dynamics

3.3.1. Market Drivers

3.3.1.1.         Impact Analysis of Market Drivers

3.3.2. Market Restraints

3.3.2.1.         Impact Analysis of Market Restraints

3.3.3. Market Opportunities

3.3.3.1.         Impact Analysis of Market Opportunities

3.3.4. Market Challenges

3.3.4.1.         Impact Analysis of Market Challenges

3.4.   Porter’s Five Forces’ Analysis

3.4.1. Bargaining Power of Suppliers

3.4.2. Bargaining Power of Buyers

3.4.3. Threat of New Entrant

3.4.4. Threat of Substitutes

3.4.5. Competitive Rivalry

3.5.   Value Chain Analysis: Global Respiratory Syndrome (MERS) Market

3.6.   COVID-19 Impact Assessment in Respiratory Syndrome (MERS) Market

3.6.1. Impact Assessment on Global Respiratory Syndrome (MERS) Market

3.6.2. Market Trends and Opportunities in the Covid-19 Landscape

Chapter 4.  Global Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

4.1.   Global Respiratory Syndrome (MERS) Market Share, By Medicine, 2017 - 2028 (USD Million)

4.1.1. REGN3048

4.1.2. REGN3051

4.1.3. GLS-5300

4.1.4. Others

Chapter 5.  Global Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

5.1.   Global Respiratory Syndrome (MERS) Market Share, By Route of Administration, 2017 - 2028 (USD Million)

5.1.1. Oral

5.1.2. Parenteral

5.1.3. Others     

Chapter 6.  Global Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

6.1.   Global Respiratory Syndrome (MERS) Market Share, By End-Users, 2017 - 2028 (USD Million)

6.1.1. Hospital Pharmacy

6.1.2. Online Pharmacy

6.1.3. Retail Pharmacy

Chapter 7.  Global Respiratory Syndrome (MERS) Market Overview, By Geography, 2017 - 2028 (USD Million)

7.1.   Global Respiratory Syndrome (MERS) Market Share, By Geography, 2017 - 2028 (USD Million)

7.1.1. Market Size and Projections, by Countries, 2017 - 2028 (USD Million)

7.1.2. Market Share and CAGR Comparison, by Countries, 2021 (%)

Chapter 8.  North America Respiratory Syndrome (MERS) Market Overview, By Countries, 2017 - 2028 (USD Million)

8.1.     North America Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

8.1.1.     Market size and projections, 2017 - 2028 (USD Million)

8.1.2.     North America Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

8.1.3.     North America Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

8.1.4.     North America Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

8.2.     North America Respiratory Syndrome (MERS) Market Overview, By Countries, 2017 - 2028 (USD Million)

8.2.1.     U.S. Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

8.2.1.1.         U.S. Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

8.2.1.2.         U.S. Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

8.2.1.3.         U.S. Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

8.2.2.     Canada Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

8.2.2.1.         Canada Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

8.2.2.2.         Canada Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

8.2.2.3.         Canada Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

8.2.3.     Mexico Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

8.2.3.1.         Mexico Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

8.2.3.2.         Mexico Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

8.2.3.3.         Mexico Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

Chapter 9.  Europe Respiratory Syndrome (MERS) Market Overview, By Countries, 2017 - 2028 (USD Million)

9.1.     Europe Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

9.1.1. Market size and projections, 2017 - 2028 (USD Million)

9.1.2.     Europe Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

9.1.3.     Europe Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

9.1.4.     Europe Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

9.2.     Europe Respiratory Syndrome (MERS) Market Overview, By Countries, 2017 - 2028 (USD Million)

9.2.1.     Germany Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

9.2.1.1.         Germany Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

9.2.1.2.         Germany Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

9.2.1.3.         Germany Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

9.2.2.     France Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

9.2.2.1.         France Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

9.2.2.2.         France Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

9.2.2.3.         France Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

9.2.3.     UK Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

9.2.3.1.         UK Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

9.2.3.2.         UK Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

9.2.3.3.         UK Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

9.2.4.     Italy Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

9.2.4.1.         Italy Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

9.2.4.2.         Italy Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

9.2.4.3.         Italy Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

9.2.5.     Spain Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

9.2.5.1.         Spain Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

9.2.5.2.         Spain Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

9.2.5.3.         Spain Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

9.2.6.     NORDIC Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

9.2.6.1.         NORDIC Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

9.2.6.2.         NORDIC Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

9.2.6.3.         NORDIC Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

9.2.7.     Russia and CIS Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

9.2.7.1.         Russia and CIS Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

9.2.7.2.         Russia and CIS Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

9.2.7.3.         Russia and CIS Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

9.2.8.     Rest of Europe Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

9.2.8.1.         Rest of Europe Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

9.2.8.2.         Rest of Europe Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

9.2.8.3.         Rest of Europe Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

Chapter 10.      Asia Pacific Respiratory Syndrome (MERS) Market Overview, By Countries, 2017 - 2028 (USD Million)

10.1.  Asia Pacific Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

10.1.1.   Market size and projections, 2017 - 2028 (USD Million)

10.1.2.   Asia Pacific Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

10.1.3.   Asia Pacific Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

10.1.4.   Asia Pacific Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

10.2.  Asia Pacific Respiratory Syndrome (MERS) Market Overview, By Countries, 2017 - 2028 (USD Million)

10.2.1.   India Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

10.2.1.1.       India Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

10.2.1.2.       India Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

10.2.1.3.       India Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

10.2.2.   China Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

10.2.2.1.       China Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

10.2.2.2.       China Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

10.2.2.3.       China Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

10.2.3.   Japan Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

10.2.3.1.       Japan Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

10.2.3.2.       Japan Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

10.2.3.3.       Japan Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

10.2.4.   ASEAN Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

10.2.4.1.       ASEAN Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

10.2.4.2.       ASEAN Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

10.2.4.3.       ASEAN Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

10.2.5.   South Korea Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

10.2.5.1.       South Korea Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

10.2.5.2.       South Korea Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

10.2.5.3.       South Korea Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

10.2.6.   Australia Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

10.2.6.1.       Australia Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

10.2.6.2.       Australia Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

10.2.6.3.       Australia Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

10.2.7.   Rest of Asia Pacific Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

10.2.7.1.       Rest of Asia Pacific Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

10.2.7.2.       Rest of Asia Pacific Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

10.2.7.3.       Rest of Asia Pacific Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

Chapter 11.      South America Respiratory Syndrome (MERS) Market Overview, By Countries, 2017 - 2028 (USD Million)

11.1.  South America Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

11.1.1.   Market size and projections, 2017 - 2028 (USD Million)

11.1.2.   South America Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

11.1.3.   South America Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

11.1.4.   South America Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

11.2.  South America Respiratory Syndrome (MERS) Market Overview, By Countries, 2017 - 2028 (USD Million)

11.2.1.   Brazil Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

11.2.1.1.       Brazil Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

11.2.1.2.       Brazil Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

11.2.1.3.       Brazil Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

11.2.2.   Argentina Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

11.2.2.1.       Argentina Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

11.2.2.2.       Argentina Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

11.2.2.3.       Argentina Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

11.2.3.   Rest of South America Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

11.2.3.1.       Rest of South America Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

11.2.3.2.       Rest of South America Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

11.2.3.3.       Rest of South America Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

Chapter 12.      Middle East & Africa Respiratory Syndrome (MERS) Market Overview, By Countries, 2017 - 2028 (USD Million)

12.1.  Middle East & Africa Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

12.1.1.   Market size and projections, 2017 - 2028 (USD Million)

12.1.2.   Middle East & Africa Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

12.1.3.   Middle East & Africa Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

12.1.4.   Middle East & Africa Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

12.2.  Middle East & Africa Respiratory Syndrome (MERS) Market Overview, By Countries, 2017 - 2028 (USD Million)

12.2.1.   GCC Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

12.2.1.1.       GCC Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

12.2.1.2.       GCC Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

12.2.1.3.       GCC Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

12.2.2.   South Africa Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

12.2.2.1.       South Africa Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

12.2.2.2.       South Africa Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

12.2.2.3.       South Africa Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

12.2.3.   Rest of Middle East & Africa Respiratory Syndrome (MERS) Market Overview, 2017 - 2028 (USD Million)

12.2.3.1.       Rest of Middle East & Africa Respiratory Syndrome (MERS) Market Overview, By Medicine, 2017 - 2028 (USD Million)

12.2.3.2.       Rest of Middle East & Africa Respiratory Syndrome (MERS) Market Overview, By Route of Administration, 2017 - 2028 (USD Million)

12.2.3.3.       Rest of Middle East & Africa Respiratory Syndrome (MERS) Market Overview, By End-Users, 2017 - 2028 (USD Million)

Chapter 13.      Competitive Landscape

13.1.  Competitive Environment, 2021

13.2.  Strategic Framework

13.2.1.   Partnership/Collaborations/Agreement

13.2.2.   Expansion

13.2.3.   Mergers & Acquisitions

13.2.4.   New Product Development

Chapter 14.      Key Vendor Analysis

14.1.              GeneOne Life Science

14.1.1.       Business Overview

14.1.2.       Product Benchmarking

14.1.3.       Financial Data

14.1.4.       Strategic Overview

14.1.5.       Key Developments

14.1.6.       SWOT Analysis

14.2.              INOVIO Pharmaceuticals

14.2.1.       Business Overview

14.2.2.       Product Benchmarking

14.2.3.       Financial Data

14.2.4.       Strategic Overview

14.2.5.       Key Developments

14.2.6.       SWOT Analysis

14.3.              Regeneron Pharmaceuticals Inc

14.3.1.       Business Overview

14.3.2.       Product Benchmarking

14.3.3.       Financial Data

14.3.4.       Strategic Overview

14.3.5.       Key Developments

14.3.6.       SWOT Analysis

14.4.              Astellas Pharma Inc.

14.4.1.       Business Overview

14.4.2.       Product Benchmarking

14.4.3.       Financial Data

14.4.4.       Strategic Overview

14.4.5.       Key Developments

14.4.6.       SWOT Analysis

14.5.              Merck KGaA

14.5.1.       Business Overview

14.5.2.       Product Benchmarking

14.5.3.       Financial Data

14.5.4.       Strategic Overview

14.5.5.       Key Developments

14.5.6.       SWOT Analysis

14.6.              Sanofi

14.6.1.       Business Overview

14.6.2.       Product Benchmarking

14.6.3.       Financial Data

14.6.4.       Strategic Overview

14.6.5.       Key Developments

14.6.6.       SWOT Analysis

14.7.              Biocare Medical, LLC

14.7.1.       Business Overview

14.7.2.       Product Benchmarking

14.7.3.       Financial Data

14.7.4.       Strategic Overview

14.7.5.       Key Developments

14.7.6.       SWOT Analysis

14.8.              Teva Pharmaceutical Industries Ltd

14.8.1.       Business Overview

14.8.2.       Product Benchmarking

14.8.3.       Financial Data

14.8.4.       Strategic Overview

14.8.5.       Key Developments

14.8.6.       SWOT Analysis

Chapter 15.   Future Outlook of the Market